Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 22 min ago
Peer-reviewedLicence not statedJAMA

Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer

  • Jamie E. Chaft1,2
  • Zhuoxin Sun3,4
  • Charles M. Rudin1,2
  • Onkar V. Khullar5
  • Charles B. Simone1
  • Kurt R. Oettel6
  • David Kozono3
  • Rajitha Sunkara3
  • Bryan Andrew Faller7
  • James M. Isbell1
  • Vladimir Hugec8
  • Asheesh Shipstone9
17 more authors
  • Eric C. McGary10
  • Jeffrey M. Clarke11
  • Ashita D. Talsania12
  • Li Ding13
  • Ramaswamy Govindan14
  • Jacob M. Sands3
  • John Victor Heymach15
  • Luis Estuardo Raez16
  • Shakun M. Malik17
  • Thomas E. Stinchcombe11
  • Sumithra J. Mandrekar18
  • J.D. Bradley19
  • David E. Gerber20
  • Everett Vokes21
  • David R. Gandara22
  • Charles Staley5
  • Suresh S. Ramalingam5
22 affiliations
  1. 1Memorial Sloan Kettering Cancer Center New York, New York
  2. 2Weill Cornell Medical College, New York, New York
  3. 3Dana-Farber Cancer Institute, Boston, Massachusetts
  4. 4Harvard T.H. Chan School of Public Health, Boston, Massachusetts
  5. 5Emory University, Winship Cancer Institute, Atlanta, Georgia
  6. 6Gundersen Lutheran Medical Center, La Crosse, Wisconsin
  7. 7Heartland Cancer Research NCORP, St Louis, Missouri
  8. 8Minnesota Oncology Hematology PA, Maplewood
  9. 9Wellmont Medical Associates—Bristol, Kingsport, Tennessee
  10. 10Kaiser Permanente, Los Angeles, California
  11. 11Duke Cancer Institute, Durham, North Carolina
  12. 12Smilow Cancer Hospital – Torrington Care Center, Torrington, Connecticut
  13. 13Saint Joseph Mercy Hospital, Ann Arbor, Michigan
  14. 14Alvin J. Siteman Cancer Center at Washington University School of Medicine, St Louis, Missouri
  15. 15MD Anderson Cancer Center, Houston, Texas
  16. 16Memorial Cancer Institute/Florida International University, Miami
  17. 17Cancer therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
  18. 18Mayo Clinic, Rochester, Minnesota
  19. 19University of Pennsylvania, Abramson Cancer Center, Philadelphia
  20. 20Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas
  21. 21University of Chicago Comprehensive Cancer Center, Chicago, Illinois
  22. 22University of California Davis Comprehensive Cancer Center, Sacramento
Open at sourceDOICite

Related

  1. Adjuvant alectinib versus crizotinib in completely resected ALK-positive non-small-cell lung cancer: a real-world retrospective cohort study
    Translational Lung Cancer ResearchPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  2. Adjuvant EGFR-TKI therapy in completely resected non–small cell lung cancer with major uncommon EGFR mutations: a real-world study
    Juemin Yu, Jialiang Wen, Tao Chen +8
    BMC MedicinePeer-reviewedCC BY-NC-ND 4.0General medicineCrossref
  3. Updated outcomes of AdjuMel study: real-world data in patients with resected stage III-IV melanoma treated with adjuvant nivolumab in France
    S. Dalle, P. Saiag, C. Lebbé +13
    European journal of cancer skin cancerPeer-reviewedCC BY-NC-ND 4.0Full text1 citedImmunologyEpidemiology & public healthHAL
  4. Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel
    Stéphane Dalle, Philippe Saiag, Céleste Lebbé +12
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textOncologyHAL
  5. Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial
    Hideaki Bando, Jun Watanabe, Yusuke Takahashi +31
    Nature MedicinePeer-reviewedCC BY-NC-NDFull text18 citedOncologyOpenAlex

Cite

BibTeXRIS
BibTeX
@article{chaft2026adjuvant,
  title = {{Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer}},
  author = {Jamie E. Chaft and Zhuoxin Sun and Charles M. Rudin and Onkar V. Khullar and Charles B. Simone and Kurt R. Oettel and David Kozono and Rajitha Sunkara and Bryan Andrew Faller and James M. Isbell and Vladimir Hugec and Asheesh Shipstone and Eric C. McGary and Jeffrey M. Clarke and Ashita D. Talsania and Li Ding and Ramaswamy Govindan and Jacob M. Sands and John Victor Heymach and Luis Estuardo Raez and Shakun M. Malik and Thomas E. Stinchcombe and Sumithra J. Mandrekar and J.D. Bradley and David E. Gerber and Everett Vokes and David R. Gandara and Charles Staley and Suresh S. Ramalingam},
  journal = {JAMA},
  year = {2026},
  month = jun,
  doi = {10.1001/jama.2026.8992},
  url = {https://pmc.ncbi.nlm.nih.gov/articles/PMC13227333/},
}
RIS
TY  - JOUR
TI  - Adjuvant Nivolumab vs Observation in Resected Non–Small Cell Lung Cancer
AU  - Jamie E. Chaft
AU  - Zhuoxin Sun
AU  - Charles M. Rudin
AU  - Onkar V. Khullar
AU  - Charles B. Simone
AU  - Kurt R. Oettel
AU  - David Kozono
AU  - Rajitha Sunkara
AU  - Bryan Andrew Faller
AU  - James M. Isbell
AU  - Vladimir Hugec
AU  - Asheesh Shipstone
AU  - Eric C. McGary
AU  - Jeffrey M. Clarke
AU  - Ashita D. Talsania
AU  - Li Ding
AU  - Ramaswamy Govindan
AU  - Jacob M. Sands
AU  - John Victor Heymach
AU  - Luis Estuardo Raez
AU  - Shakun M. Malik
AU  - Thomas E. Stinchcombe
AU  - Sumithra J. Mandrekar
AU  - J.D. Bradley
AU  - David E. Gerber
AU  - Everett Vokes
AU  - David R. Gandara
AU  - Charles Staley
AU  - Suresh S. Ramalingam
PY  - 2026
DA  - 2026/06/01
JO  - JAMA
DO  - 10.1001/jama.2026.8992
UR  - https://pmc.ncbi.nlm.nih.gov/articles/PMC13227333/
SN  - 0002-9955
SN  - 0098-7484
SN  - 1538-3598
SN  - 2376-8118
ER  -